Arcellx, Inc. NASDAQ:ACLX

Arcellx stock price today

$72
-7.07
-8.95%
Financial Health
0
1
2
3
4
5
6
7
8
9

Arcellx stock price monthly change

+26.67%
month

Arcellx stock price quarterly change

+26.67%
quarter

Arcellx stock price yearly change

+37.32%
year

Arcellx key metrics

Market Cap
4.05B
Enterprise value
1.07B
P/E
-5.57
EV/Sales
N/A
EV/EBITDA
-4.30
Price/Sales
N/A
Price/Book
5.10
PEG ratio
-0.40
EPS
-1.07
Revenue
131.66M
EBITDA
-66.94M
Income
-50.54M
Revenue Q/Q
119.16%
Revenue Y/Y
635.05%
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
-50.84%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Arcellx stock price history

Arcellx stock forecast

Arcellx financial statements

Average Price Target
Last Year

$111.6

Potential upside: 54.99%

Based on estimate of 5 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Arcellx, Inc. (NASDAQ:ACLX): Profit margin
Jun 2023 14.30M -23.85M -166.79%
Sep 2023 14.95M -39.33M -262.99%
Dec 2023 63.14M 19.84M 31.42%
Mar 2024 39.25M -7.19M -18.34%
Arcellx, Inc. (NASDAQ:ACLX): Earnings per share (EPS)
2023-11-13 -0.56 -0.81
2024-02-28 -0.61 0.42
2024-05-09 -0.51 -0.14
Arcellx, Inc. (NASDAQ:ACLX): Debt to assets
Jun 2023 623528000 329.86M 52.9%
Sep 2023 614218000 348.09M 56.67%
Dec 2023 825132000 339.75M 41.18%
Mar 2024 779695000 283.12M 36.31%
Arcellx, Inc. (NASDAQ:ACLX): Cash Flow
Jun 2023 -22.61M 51.27M 116K
Sep 2023 -10.10M -160.02M -4.98M
Dec 2023 58.24M 21.01M 188.59M
Mar 2024 -31.90M -206.81M -2.98M

Arcellx alternative data

Arcellx, Inc. (NASDAQ:ACLX): Employee count
Sep 2023 98
Oct 2023 98
Nov 2023 98
Dec 2023 98
Jan 2024 98
Feb 2024 98
Mar 2024 130
Apr 2024 130
May 2024 130
Jun 2024 130
Jul 2024 130

Arcellx other data

45.96% -49.60%
of ACLX is owned by hedge funds
16.70M -25.16M
shares is hold by hedge funds

Arcellx, Inc. (NASDAQ:ACLX): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 45185
Feb 2024 0 48176
Mar 2024 0 566903
Apr 2024 0 32488
May 2024 0 30289
Jul 2024 0 39352
Aug 2024 0 48634
Sep 2024 0 47372
Oct 2024 0 3000
Nov 2024 0 73094
Dec 2024 0 3000
Transaction Date Insider Security Shares Price per share Total value Source
Option
PATEL KAVITA director
Stock Option (right to buy) 1,500 $6.66 $9,990
Option
PATEL KAVITA director
Common Stock 1,500 $6.66 $9,990
Sale
PATEL KAVITA director
Common Stock 1,400 $76.92 $107,689
Sale
PATEL KAVITA director
Common Stock 100 $77.61 $7,761
Option
PATEL KAVITA director
Stock Option (right to buy) 1,500 $6.66 $9,990
Option
PATEL KAVITA director
Common Stock 1,500 $6.66 $9,990
Sale
PATEL KAVITA director
Common Stock 300 $88.53 $26,559
Sale
PATEL KAVITA director
Common Stock 400 $89.84 $35,937
Sale
PATEL KAVITA director
Common Stock 200 $91.91 $18,381
Sale
PATEL KAVITA director
Common Stock 300 $93.76 $28,127
Monday, 23 December 2024
zacks.com
Monday, 9 December 2024
investors.com
benzinga.com
Sunday, 8 December 2024
businesswire.com
Wednesday, 13 November 2024
zacks.com
Friday, 8 November 2024
zacks.com
Thursday, 7 November 2024
zacks.com
zacks.com
Tuesday, 10 September 2024
seekingalpha.com
Thursday, 8 August 2024
zacks.com
Thursday, 4 July 2024
investorplace.com
Wednesday, 26 June 2024
seekingalpha.com
Monday, 27 May 2024
investorplace.com
Thursday, 9 May 2024
Zacks Investment Research
InvestorPlace
Thursday, 4 April 2024
Zacks Investment Research
Wednesday, 20 March 2024
Business Wire
Wednesday, 28 February 2024
Zacks Investment Research
Thursday, 15 February 2024
InvestorPlace
Tuesday, 16 January 2024
InvestorPlace
Friday, 15 December 2023
InvestorPlace
Thursday, 30 November 2023
InvestorPlace
Thursday, 16 November 2023
Zacks Investment Research
Wednesday, 15 November 2023
Proactive Investors
Market Watch
Thursday, 9 November 2023
Zacks Investment Research
Zacks Investment Research
Thursday, 2 November 2023
Zacks Investment Research
Monday, 23 October 2023
InvestorPlace
Tuesday, 17 October 2023
Zacks Investment Research
  • What's the price of Arcellx stock today?

    One share of Arcellx stock can currently be purchased for approximately $72.

  • When is Arcellx's next earnings date?

    Unfortunately, Arcellx's (ACLX) next earnings date is currently unknown.

  • Does Arcellx pay dividends?

    No, Arcellx does not pay dividends.

  • How much money does Arcellx make?

    Arcellx has a market capitalization of 4.05B. Arcellx made a loss 70.69M US dollars in net income (profit) last year or -$0.14 on an earnings per share basis.

  • What is Arcellx's stock symbol?

    Arcellx, Inc. is traded on the NASDAQ under the ticker symbol "ACLX".

  • What is Arcellx's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Arcellx?

    Shares of Arcellx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Arcellx have?

    As Jul 2024, Arcellx employs 130 workers.

  • When Arcellx went public?

    Arcellx, Inc. is publicly traded company for more then 3 years since IPO on 4 Feb 2022.

  • What is Arcellx's official website?

    The official website for Arcellx is arcellx.com.

  • Where are Arcellx's headquarters?

    Arcellx is headquartered at 25 West Watkins Mill Road, Gaithersburg, MD.

  • How can i contact Arcellx?

    Arcellx's mailing address is 25 West Watkins Mill Road, Gaithersburg, MD and company can be reached via phone at +240 3270603.

  • What is Arcellx stock forecast & price target?

    Based on 5 Wall Street analysts` predicted price targets for Arcellx in the last 12 months, the avarage price target is $111.6. The average price target represents a 54.99% change from the last price of $72.

Arcellx company profile:

Arcellx, Inc.

arcellx.com
Exchange:

NASDAQ

Full time employees:

130

Industry:

Biotechnology

Sector:

Healthcare

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

25 West Watkins Mill Road
Gaithersburg, MD 20878

CIK: 0001786205
ISIN: US03940C1009
CUSIP: 03940C100